Skip to main content
. 2021 Feb;9(3):245. doi: 10.21037/atm-20-4707

Figure 4.

Figure 4

Safety assessment of human iRPE cells in vitro and in vivo. Immunofluorescence images show anti-Ki-67 antibody staining of cultured human iRPE cells at 15 days (B) and 25 days (E) after passage. Nuclei were (blue) stained with DAPI (A,D), and merged images are shown in the panels (C,F). Scale bars, 25 µm (A,B,C), and 100 µm (D,E,F). Flow cytometric analysis was used to determine the percentage of Ki-67-positive cells at 5 days (H) and 24 days (I), indicating the proliferative ability of cultured iRPE cells. The percentage of Ki-67-positive cells decreased significantly at 24 days compared with that of the cells at 5 days. iRPE cells at 5 days were not stained with anti-Ki-67 antibody as a control (G). Tumorigenesis tests of cultured iRPE cells and human iPSCs in immunodeficient NSG mice. No obvious positive characteristics were found in the iRPE-injected group (L). After different doses of human iPSC injection, eyeballs displayed tumor formation (J, K), n=8–10 eyes/group. Magnified photographs are appended in the bottom right corner.